July 7, 2020 / 9:39 AM / a month ago

BRIEF-Lipidor Signs Agreement With Cro

July 7 (Reuters) - Lipidor AB:

* LIPIDOR SIGNS AGREEMENT WITH CRO FOR IMPLEMENTATION OF PHASE III CLINICAL STUDY OF DRUG CANDIDATE AKP-02 AGAINST PSORIASIS

* LIPIDOR AB - STUDY IS EXPECTED TO COMMENCE IN Q1 2021 WITH FINAL REPORTING IN Q1 2022.

* LIPIDOR AB - COST OF PHASE III STUDY IS COVERED BY LIPIDOR’S EXISTING FUNDS.

* LIPIDOR AB - DISCUSSIONS WITH CLINICAL TRIAL MATERIAL MANUFACTURERS ARE ONGOING AND AN AGREEMENT IS EXPECTED TO BE IN PLACE IN Q3 2020. Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below